SARS-COV-2 Seroconversion in Asymptomatic Individuals

The main purpose of this study is to determine what proportion of individuals have developed natural immunity to SARS-CoV-2 through a prior, symptomatic or silent exposure to the virus.

Data from the first phase of the study was published as a preprint in JCI Insight on March 15, 2021. Read more here

The data show that a much higher proportion of the adult population than originally anticipated have some pre-existing immune cross-reactivity against the SARS-CoV-2 virus.

You can read more about this story here too:

Why do some people experience mild COVID-19 symptoms and others have severe illness? Pre-existing antibodies could explain the range of COVID-19 illness

You can read more about these results in an earlier news article in the National Post

In the next phase of the study, we are investigating the impact this has on how individuals respond to the SARS-CoV-2 vaccines and whether it can explain why some adults get more severe COVID-19 than others, in addition to other factors such as age, sex and chronic illnesses.